Finance

Lists
Why is TVRD down 5,61%?
Dive Deeper
TVRD:NASDAQ
Tvardi Therapeutics Inc
1,01 USD
-5,61%
(-0,060) 1D
0,99 USD
-2,00% (-0,020)
After hours
Closed: 16-окт., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TVRD...
Open
1,05 USD
High
1,07 USD
Low
1,00 USD
Mkt. cap
13,47 млн
Avg. vol.
201,82 миң
Volume
91,84 миң
52-wk high
6,65 USD
52-wk low
0,93 USD
EPS
-2,78 USD
Beta
0,37
Shares outstanding
13,34 млн
No. of employees
12
Open
1,05 USD
High
1,07 USD
Low
1,00 USD
Mkt. cap
13,47 млн
Avg. vol.
201,82 миң
Volume
91,84 миң
52-wk high
6,65 USD
52-wk low
0,93 USD
EPS
-2,78 USD
Beta
0,37
Shares outstanding
13,34 млн
No. of employees
12
News stories
From web sources and news partners
About Tvardi Therapeutics Inc
CEO-
Employees12
Founded2017
HeadquartersШугар Ленд, Техас, Америка Кошмо Штаттары
SectorPharmaceutical industry
Websitetvarditherapeutics.com
Analyst ratings
Based on 6 analysts giving stock ratings to TVRD in the past 3 months
Buy
Buy
4
Hold
1
Sell
1
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for TVRD in the last 3 months.
Highest
Current 1,01 USD
14,00 USD (+1 286,14%)
Average
8,20 USD (+711,88%)
Lowest
3,00 USD (+197,03%)
Analyst
Recommendation
Action
Price target
Projected
Date
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
10,00 USD
+890,1%
09/15/2026
Elemer Piros
Lucid Capital
Buy
Initiated
14,00 USD
+1 286,1%
09/08/2026
Sara Nik
H.C. Wainwright
Buy
Maintained
9,00 USD
+791,1%
08/21/2026
Unknown Analyst
Cantor Fitzgerald
Hold
Maintained
-
-
08/19/2026
Julian Harrison
BTIG
Buy
Maintained
5,00 USD
+395%
08/19/2026
Etzer Darout
Barclays
Sell
Maintained
3,00 USD
+197%
08/20/2026
Yasmeen Rahimi
Piper Sandler
Buy
Upgraded
13,00 USD
+1 187,1%
07/08/2026
Ryan Deschner
Raymond James
Buy
Upgraded
10,00 USD
+890,1%
07/08/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
10,00 USD
+890,1%
05/11/2026
Jay Olson
Oppenheimer
Buy
Maintained
10,00 USD
+890,1%
05/11/2026
Steven Seedhouse
Cantor Fitzgerald
Hold
Maintained
-
-
04/01/2026
Christopher Liu
Lucid Capital
Buy
Upgraded
6,00 USD
+494,1%
02/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
3,60 млн
5,49 млн
4,91 млн
4,00 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,34 млн
2,10 млн
2,14 млн
2,63 млн
Operating expense
5,94 млн
7,59 млн
7,05 млн
6,63 млн
Total operating expenses
5,94 млн
7,59 млн
7,05 млн
6,63 млн
Operating income
-5,94 млн
-7,59 млн
-7,05 млн
-6,63 млн
Other non operating income
-
-
-
-
EBT including unusual items
-5,53 млн
-7,28 млн
-6,80 млн
-6,46 млн
EBT excluding unusual items
-5,53 млн
-7,28 млн
-6,80 млн
-6,46 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-5,53 млн
-7,28 млн
-6,80 млн
-6,46 млн
Net profit margin
-
-
-
-
Earnings per share
-0,59
-0,78
-0,73
-0,69
Interest and investment income
411,00 миң
312,00 миң
247,00 миң
172,00 миң
Interest expense
-
-
-
-
Net interest expenses
411,00 миң
312,00 миң
247,00 миң
172,00 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-5,91 млн
-7,56 млн
-7,03 млн
-6,61 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору